Aubrey Crispen, Athens: She hammered two home runs and drove in five as Athens topped Petersburg PORTA 11-6 in a Sangamo ...

Another company looking to initiate clinical trials with an epigenetic-editor-based treatment for hepatitis is nChroma Bio.

Eli Lilly and Sangamo Therapeutics have entered into a licensing agreement worth over $1.4bn to deliver genomic medicines for ...

Sangamo Therapeutics Inc., a genomic medicine company, has entered into a license agreement with Eli Lilly and Company.

The recent decline in major indices, with the S&P 500 down nearly 5% and the Nasdaq nearly 6%, has ushered in increased scrutiny on five notable stocks: RH, Five Below, Sangamo Therapeutics, Bank of ...

Sangamo Therapeutics Inc. is adding a much-needed $18 million up-front payment in a neurology-focused deal with Eli Lilly and Co. that could bring up to an additional $1.4 billion. In return, Lilly ...

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for investors. Click for my SGMO stock update.

Struggling US genomic medicines company Sangamo Therapeutics (Nasdaq: SGMO) has been offered a lifeline via a licensing deal with pharma major Eli Lilly (NYSE: LLY), sending its share up 24% to $0.77.

Eli Lilly’s stock slipped during a broader market nosedive sparked by Trump’s tariff barrage, but retail traders oddly found reasons to cheer. The pharmaceutical sector mostly dodged the tariff bullet ...

Eli Lil­ly is li­cens­ing Sang­amo Ther­a­peu­tics’ AAV cap­sid for an undis­closed CNS dis­ease tar­get, and the $18 mil­lion up­front fee should give the be­lea­guered biotech … ...